...
首页> 外文期刊>Journal of thrombosis and thrombolysis >Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis
【24h】

Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis

机译:在新口服抗凝剂和维生素K拮抗剂之间不间断抗凝的心房颤动消融血栓栓塞和出血风险:来自更新的荟萃分析的见解

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cumulative reports comparing the efficacy and safety outcomes between uninterrupted NOACs and vitamin K antagonists (VKA) in AF ablation had been freshly published. This meta-analysis aimed at offering a more comprehensive evaluation between these two anticoagulants in uninterrupted strategy. We searched in PUBMED, EMBASE, and Cochrane Library (inception to June 10, 2019) for eligible studies. Fixed-effects model was preferred in pooled analysis if I-2 = 2 and target activated clotting time (ACT) > 300 s. In conclusions, uninterrupted NOACs was more effective than uninterrupted VKA in reducing major bleeding and pericardial effusion risk without increasing thromboembolism risk, and the benefits of uninterrupted NOACs on major bleeding complication could be more pronounced if CHA(2)DS(2)-VASc score >= 2 or target ACT > 300 s.
机译:累积报告比较AF消融中不间断的Noacs和维生素K拮抗剂(VKA)之间的疗效和安全结果已经新出版。 这种荟萃分析旨在在不间断的策略中提供这两种抗凝血剂之间的更全面的评估。 我们在Pubmed,Embase和Cochrane图书馆搜索(开始于2019年6月10日)进行合格研究。 如果I-2 = 2和靶激活凝血时间(ACT)> 300秒,则固定效果模型是优选的。 在结论中,不间断的Noacs比不间断的VKA更有效地降低重大出血和心包积液风险而不会增加血栓栓塞风险,并且如果CHA(2)DS(2)-vasc评分,则不间断脱落对主要出血并发症的益处可能会更加明显。 > = 2或目标法案> 300秒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号